Skip to main content
. 2024 Feb 28;134(7):913–930. doi: 10.1161/CIRCRESAHA.122.321292

Figure 8.

Figure 8.

Cardiomyocyte-specific deletion of ROBO1 reduces cardiac hypertrophy and dysfunction after transverse aortic constriction (TAC). A, Schematic of Robo1fl/fl mouse model and PCR analysis for quantitation of loxp-flanked Robo1 gene region in wild-type (WT), heterozygous (loxp/-), or homozygous (loxp/loxp) mice. B, Immunofluorescence staining using anti-cardiac troponin (c-TNT) antibody (red), anti-ROBO1 antibody (green), and 4’,6-diamidino-2-phenylindole (DAPI; blue) of heart sections from Robo1fl/fl control or Myh6-CreERT2;Robo1fl/fl mice. C, B-mode and M-mode echocardiographies of Robo1fl/fl or Myh6-CreERT2;Robo1fl/fl mice after sham or TAC surgery with analysis of ejection fraction (EF), fractional shortening (FS), relative end-diastolic left ventricle posterior wall thickness (LVPWd), and relative left ventricle mass. N=8 mice/group. D, Explanted hearts from Robo1fl/fl and Myh6-MerCreMer;Robo1fl/fl mice after sham or TAC surgery (top); representative images of heart sections stained with hematoxylin & eosin (H&E; scale bar, 500 µm; middle); and representative images of wheat germ agglutinin (WGA)–stained heart sections (scale bar, 20 µm; bottom). E, Heart weight to body weight (HW/BW) ratio in Robo1fl/fl and Myh6-MerCreMer mice after sham or TAC surgery. N=8 mice/group. F, Quantification of myocyte cross-sectional area on WGA staining. G, Quantitative PCR (qPCR) analysis of transcription of hypertrophy-related genes (Nppa, Nppb, Myh7, and Acta1, normalized to Gapdh mRNA levels) in hearts from Robo1fl/fl or Myh6-MerCreMer;Robo1fl/fl mice after sham or TAC surgery. Two-way ANOVA and the Tukey multiple comparisons test were used for all comparisons.